Hansa Biopharma Ab · OMXSTO:HNSA
Hansa Biopharma Ab — Q4 2024 Earnings Presentation
20 slides from Hansa Biopharma Ab's earnings presentation, Feb 6, 2025
Slide 1: Q4 and Full Year Results Conference Call
Q4 and Full Year Results Conference Call February 6, 2025
Slide 2: Forward-looking statements
Forward-looking statements This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will occ
Slide 3: Q4 and Full Year Results Conference Call Agenda
Q4 and Full Year Results Conference Call Agenda 6 February 2025 CEO Remarks Søren Tulstrup Chief Executive Officer, President Operational Update Søren Tulstrup Chief Executive Officer, President Pipeline Update Hitto Kaufmann Chief R&D Officer Financial Results Evan Ballantyne Chief Financial Office
Slide 4: Strong full year 2024 IDEFIRIX sales performance
Strong full year 2024 IDEFIRIX sales performance Full Year 2024 Performance Including Provision High Double-digit Revenue Growth FY Sales 189.7 MSEK 140.1 MSEK (vs prior year) Revenue FY Total Revenue 220.9 MSEK 171.3 MSEK ✓ 83% increase in FY Sales Q4 2024 Performance ✓ 35% increase in IDEFIRIX sal
Slide 5: Quarterly performance remains solid despite continued fluctuation in organ allocation system
Quarterly performance remains solid despite continued fluctuation in organ allocation system Quarter on Quarter Performance TTM Quarter on Quarter Performance TTM *including provision TTM: trailing 12 month © 2025 H ansa Biopharma AB
Slide 6: Significant pipeline progress in 2024
Significant pipeline progress in 2024 ConfIdeS Ph 3 PAES Ph 3 GOOD-IDES-02 Ph 3 15-HMedIdeS-09 Ph 3 (kidney transplant) (kidney transplant) (anti-GBM) (GBS) Enrolment complete 96% enrolled Enrolment complete Positive study and indirect data read out 2H 2025 complete enrolment 2025 data read out 2025
Slide 7: IDEFIRIX EU launch remains on track
IDEFIRIX EU launch remains on track Clinical Patient Selection Market Readiness & Treatment Access 114 clinics are IDEFIRIX ready 282 local scientific events and Reimbursement in 18 markets to treat KOL engagement incl. largest EU markets *3 additional markets in Jan 2025 36 centers with clinical 7
Slide 8: Q4 and Full Year 2024 Results Conference
Q4 and Full Year 2024 Results Conference 6 February 2025 CEO Remarks Søren Tulstrup Chief Executive Officer, President Operational Update Søren Tulstrup Chief Executive Officer, President Pipeline Update Hitto Kaufmann Chief R&D Officer Financial Results Evan Ballantyne Chief Financial Officer Q&A a
Slide 9: Broad clinical pipeline
Broad clinical pipeline Marketing Preclinical Phase 1 Phase 2 Phase 3 Marketed Partner Sta tus Next anticipate d milestone authoriza tion Imlifidase EU: Kid ney transplan tation in highly Commercialization ongoing EU: Additional agreements around sensitized patients 1 ,2 Post approval Clinical reimb
Slide 10: Advancing the science in Autoimmune, Gene Therapy, and Transplantation
Advancing the science in Autoimmune, Gene Therapy, and Transplantation TRANSPLANT AUTOIMMUNE TRANSPLANTATION Delivering the Pipeline 15-HMedIdeS-09 Ph 2 (GBS) US ConfIdeS Ph 3 (kidney) Indirect Treatment Comparison and Enrolment COMPLETE 8 Ongoing clinical trials in autoimmune, Full data read out CO
Slide 11: 15-HMedIdeS-09 Phase 2 Study demonstrated the role imlifidase may play in halting the progression of GBS
15-HMedIdeS-09 Phase 2 Study demonstrated the role imlifidase may play in halting the progression of GBS Study Overview • Open-label, single arm, multi-center study across the UK, France, and the Netherlands. Patients with severe GBS were included (GBS DS ≥ 3) • Evaluated safety, tolerability, and e
Slide 12: Imlifidase in combination with IVIg delivered clinically meaningful benefit to patients with severe GBS
Imlifidase in combination with IVIg delivered clinically meaningful benefit to patients with severe GBS Substantial early improvement in functional Significantly faster improvement in clinically status in Phase 2 study meaningful measures vs standard of care IVIg well tolerated/consistent safety pro
Slide 13: Q4 and Full Year 2024 Results Conference
Q4 and Full Year 2024 Results Conference 6 February 2025 CEO Remarks Søren Tulstrup Chief Executive Officer, President Operational Update Søren Tulstrup Chief Executive Officer, President Pipeline Update Hitto Kaufmann Chief R&D Officer Financial Results Evan Ballantyne Chief Financial Officer Q&A a
Slide 14: Strong full year IDEFIRIX sales performance with double digit growth year on year
Strong full year IDEFIRIX sales performance with double digit growth year on year Revenue (Q/Q) Product Sales (Q/Q) Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 69.5 78.4 29.7 * 29.7 * MSEK 56.0 47.4 47.1 MSEK 50.4 54.2 43.3 19.9 * 47.4 19.9 * 43.3 39.8 39.8 32.3 25.6 Product sales Pr
Slide 15: Continued investments in R&D and commercialization
Continued investments in R&D and commercialization SG&A expenses (Q/Q) R&D expenses (Q/Q) Operating loss (Q/Q) Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 -76 -80 -91 -88 -88 -92 MSEK MSEK MSEK -106 -108 -103 -101 -117 -159 -176 -174 -187 SG&A expenses (
Slide 16: Cash runway into 2026 through directed share issue in Q2'24
Cash runway into 2026 through directed share issue in Q2’24 Operating cash flow (Q/Q) Cash & Cash Equivalents (Q/Q) Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 732 MSEK 705 MSEK -149 541 554 -173 405 -189 -189 -207 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Operating cash flow (FY/FY) Number of employees (Q/Q) 2022 2023 2024
Slide 17: Q4 and Full Year 2024 Results Conference
Q4 and Full Year 2024 Results Conference 6 February 2024 CEO Remarks Søren Tulstrup Chief Executive Officer, President Pipeline Update Hitto Kaufmann Chief R&D Officer Financial Results Evan Ballantyne Chief Financial Officer Q&A and Close Søren Tulstrup Chief Executive Officer, President © 2024 H a
Slide 18: Hansa Biopharma Leadership
HANSA BIOPHARMA LEADERSHIP Søren Tulstrup Hitto Kaufmann Evan Ballantyne President & CEO Chief R&D Officer CFO © 2024 H ansa Biopharma AB
Slide 19: Hansa Biopharma contacts and key events
Hansa Biopharma contacts and key events Contacts Calendar and events Evan Ballantyne 2025 Chief Financial Officer Email: ir@hansabiopharma.com 21 MAR Annual & Sustainability Report 2024 17 APR Q1 2025 (January – March) Report 17 JULY Q2 2025 (January – June) Report Stephanie Kenney VP, Corporate Aff
Slide 20: HAN Sar
MZ HAN Sar BIOPHARMA